PT2503338E - Cd73 para monitorizar o desenvolvimento de doenças e avaliar a eficácia de terapias - Google Patents

Cd73 para monitorizar o desenvolvimento de doenças e avaliar a eficácia de terapias Download PDF

Info

Publication number
PT2503338E
PT2503338E PT12002502T PT12002502T PT2503338E PT 2503338 E PT2503338 E PT 2503338E PT 12002502 T PT12002502 T PT 12002502T PT 12002502 T PT12002502 T PT 12002502T PT 2503338 E PT2503338 E PT 2503338E
Authority
PT
Portugal
Prior art keywords
biomarker
therapies
assessing
efficacy
diseases
Prior art date
Application number
PT12002502T
Other languages
English (en)
Inventor
Sirpa Jalkanen
Marko Salmi
Markku Jalkanen
Original Assignee
Faron Pharmaceuticals Oy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Faron Pharmaceuticals Oy filed Critical Faron Pharmaceuticals Oy
Publication of PT2503338E publication Critical patent/PT2503338E/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/24—Immunology or allergic disorders
    • G01N2800/245—Transplantation related diseases, e.g. graft versus host disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/324—Coronary artery diseases, e.g. angina pectoris, myocardial infarction
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
PT12002502T 2007-10-24 2008-10-15 Cd73 para monitorizar o desenvolvimento de doenças e avaliar a eficácia de terapias PT2503338E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FI20070795A FI20070795A0 (fi) 2007-10-24 2007-10-24 Uusi biomarkkeri sairauksien kehittämisen tarkkailuun ja terapioiden tehon arviointiin

Publications (1)

Publication Number Publication Date
PT2503338E true PT2503338E (pt) 2015-03-05

Family

ID=38656804

Family Applications (2)

Application Number Title Priority Date Filing Date
PT08842581T PT2201376E (pt) 2007-10-24 2008-10-15 Um novo biomarcador para monitorizar o desenvolvimento de doenças e avaliar a eficácia de tratamentos
PT12002502T PT2503338E (pt) 2007-10-24 2008-10-15 Cd73 para monitorizar o desenvolvimento de doenças e avaliar a eficácia de terapias

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PT08842581T PT2201376E (pt) 2007-10-24 2008-10-15 Um novo biomarcador para monitorizar o desenvolvimento de doenças e avaliar a eficácia de tratamentos

Country Status (14)

Country Link
US (1) US20100209942A1 (pt)
EP (2) EP2201376B1 (pt)
JP (2) JP4982610B2 (pt)
KR (2) KR20100059902A (pt)
CA (1) CA2702635A1 (pt)
CY (2) CY1113403T1 (pt)
DK (2) DK2201376T3 (pt)
ES (2) ES2532361T3 (pt)
FI (1) FI20070795A0 (pt)
HR (2) HRP20120743T1 (pt)
PL (2) PL2201376T3 (pt)
PT (2) PT2201376E (pt)
SI (2) SI2201376T1 (pt)
WO (1) WO2009053523A1 (pt)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201704689XA (en) 2008-01-18 2017-07-28 Harvard College Methods of detecting signatures of disease or conditions in bodily fluids
TW201209171A (en) 2010-07-23 2012-03-01 Harvard College Methods of detecting diseases or conditions using phagocytic cells
KR20130041961A (ko) 2010-07-23 2013-04-25 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 체액에서 질환 또는 상태의 특징을 검출하는 방법
EP2596116A4 (en) 2010-07-23 2014-03-19 Harvard College METHODS FOR DETECTION OF AUTOIMMUNE OR IMMUNE-RELATED DISEASES / PATHOLOGIES
AU2011280936A1 (en) 2010-07-23 2013-02-28 President And Fellows Of Harvard College Methods of detecting prenatal or pregnancy-related diseases or conditions
EP2596349B1 (en) 2010-07-23 2017-12-13 President and Fellows of Harvard College Methods of detecting cardiovascular diseases or conditions
AU2013274002A1 (en) 2012-06-15 2015-02-05 Harry Stylli Methods of detecting diseases or conditions
US20150141260A1 (en) 2012-06-15 2015-05-21 Harry Stylli Methods of detecting diseases or conditions using circulating diseased cells
CN105164535B (zh) * 2013-02-14 2018-04-10 法龙药品公司 测定急性呼吸窘迫综合征(ards)相关生物标志物的方法、监测患者的ards的发展和治疗的方法
EP3385717A3 (en) 2013-03-09 2018-10-24 Harry Stylli Methods of detecting prostate cancer
EP2965077B1 (en) 2013-03-09 2022-07-13 Harry Stylli Methods of detecting cancer
EP3191846A4 (en) 2014-09-11 2018-06-13 Harry Stylli Methods of detecting prostate cancer
PL3221346T3 (pl) 2014-11-21 2021-03-08 Bristol-Myers Squibb Company Przeciwciała ze zmodyfikowanym regionem stałym łańcucha ciężkiego
NZ731633A (en) 2014-11-21 2022-01-28 Bristol Myers Squibb Co Antibodies against cd73 and uses thereof
GB201706747D0 (en) * 2017-04-27 2017-06-14 Queen Mary Method and apparatus for determining the efficacy of statins for treating inflammatory diseases in idividual patients

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU727445B2 (en) * 1995-08-18 2000-12-14 Donald W Landry Detection of organic compounds through regulation of antibody-catalyzed reactions
WO1997013875A1 (en) * 1995-10-13 1997-04-17 Imperial College Of Science, Technology & Medicine Methods for predicting the outcome of persistent hbv infection and the outcome of cytokine therapy
HUP0002003A3 (en) * 2000-05-24 2003-01-28 Pronuk Biotechnologia Kft Process and reagent-kit for determining of 5'-nucleotidase activity
US20030099608A1 (en) * 2001-03-27 2003-05-29 Presnell Scott R. Human cytokine receptor
WO2004079013A1 (en) * 2003-03-03 2004-09-16 Arizona Board Of Regents On Behalf Of The University Of Arizona Ecto-5’-nucleotidase (cd73) used in the diagnosis and the treatment of pancreatic cancer
EP1608400B1 (en) * 2003-03-28 2010-06-23 Faron Pharmaceuticals OY Elevation of adenosine level by cytokine-induced expression of cd73
FI20030467A0 (fi) * 2003-03-28 2003-03-28 Sirpa Jalkanen Menetelmä tulehdustilojen hoitamiseen
CA2528152A1 (en) * 2003-06-03 2005-01-06 The Regents Of The University Of California Compositions and methods for treatment of disease with acetylated disaccharides
ATE520979T1 (de) * 2005-08-24 2011-09-15 Bristol Myers Squibb Co Biomarker und verfahren zur bestimmung der empfindlichkeit gegenüber modulatoren des egf(epidermal growth factor)-rezeptors
FI20051003A0 (fi) 2005-10-07 2005-10-07 Faron Pharmaceuticals Oy Menetelmä iskemiareperfuusiovaurion tai monielinhäiriön hoitamiseksi tai estämiseksi
EP2021350B1 (en) * 2006-03-21 2016-12-21 Rheinische Friedrich-Wilhelms-Universität Bonn Phosphorylated a2a receptor agonists
JP2009543862A (ja) * 2006-07-14 2009-12-10 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア ガンのバイオマーカーおよびその使用方法

Also Published As

Publication number Publication date
HRP20150181T1 (hr) 2015-06-19
FI20070795A0 (fi) 2007-10-24
DK2201376T3 (da) 2012-10-15
CY1116089T1 (el) 2017-02-08
SI2503338T1 (sl) 2015-06-30
CY1113403T1 (el) 2016-06-22
DK2503338T3 (en) 2015-03-09
JP4982610B2 (ja) 2012-07-25
WO2009053523A1 (en) 2009-04-30
JP2012159514A (ja) 2012-08-23
PT2201376E (pt) 2012-08-20
EP2201376A4 (en) 2011-03-23
EP2503338B1 (en) 2014-12-24
US20100209942A1 (en) 2010-08-19
SI2201376T1 (sl) 2012-09-28
KR20100059902A (ko) 2010-06-04
PL2503338T3 (pl) 2015-06-30
JP2011501176A (ja) 2011-01-06
PL2201376T3 (pl) 2013-01-31
JP5619810B2 (ja) 2014-11-05
EP2503338A2 (en) 2012-09-26
CA2702635A1 (en) 2009-04-30
ES2532361T3 (es) 2015-03-26
EP2201376A1 (en) 2010-06-30
EP2503338A3 (en) 2013-03-13
HRP20120743T1 (hr) 2012-10-31
ES2389751T3 (es) 2012-10-31
EP2201376B1 (en) 2012-08-08
KR20160029869A (ko) 2016-03-15

Similar Documents

Publication Publication Date Title
HRP20150181T1 (hr) Cd73 kao biomarker za praä†enje razvoja bolesti i procjenu uäśinkovitosti lijeäśenja
ZA201108907B (en) New biomarkers for assessing kidney diseases
GB0724735D0 (en) Methods and biomarkers for diagnosing and monitoring psychotic disorders
GB0701626D0 (en) Methods and biomarkers for diagnosing and monitoring psychotic disorders
IL219210A0 (en) Biomarkers and methods for measuring and monitoring inflammatory disease activity
GB0624858D0 (en) Battery Monitoring
HK1162610A1 (zh) 診斷胎兒畸形的方法
EP2158326A4 (en) BIOMARKERS FOR THE DIAGNOSIS OF AUTOIMMUNE DISEASES
GB0608829D0 (en) In-situ measurement of physical parameters
GB0717637D0 (en) Future cardiac event biomarkers
GB2450351B (en) Monitoring an Immunoassay
IL206631A0 (en) Biomarkers for the prediction of renal injury
IL217725A0 (en) Means and methods for diagnosing thyroid disorders
TWI351185B (en) Methods for interference measurement and prediction
EP2222689A4 (en) THERAPEUTIC AND DIAGNOSTIC COMPOUNDS
GB0722068D0 (en) Predictive test
GB0720433D0 (en) Usage monitoring
EP2209565A4 (en) MONITORING INDEPENDENT VIBRATORS
AU2009900444A0 (en) Agents and methods for diagnosing the presence or risk of a condition
GB0606920D0 (en) Biomarker for schizophrenic disorders
PL382585A1 (pl) Sposób realizowania transakcji handlowych
PL381454A1 (pl) Sposób diagnozowania stanu technicznego obiektów mostowych
AU2008902580A0 (en) Agents and methods for diagnosing the presence or risk of a condition
GB0720545D0 (en) Diagnosing physchotic disorders
GB0622351D0 (en) Non-invasive monitoring